• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

中国药物评价 ›› 2021, Vol. 38 ›› Issue (5): 461-464.

• 药物管理 • 上一篇    

左乙拉西坦联合舍曲林对癫痫伴抑郁患者疗效、安全性及生活质量的影响

李倩   

  1. 焦作市第四人民医院, 河南 焦作 454000
  • 收稿日期:2021-05-24 修回日期:2021-09-08 出版日期:2021-10-28 发布日期:2021-10-28

Effect of Levetiracetam Combined with Sertraline on Efficacy, Safety and Quality of Life in Patients with Epilepsy and Depression

  1. Jiaozuo Fourth People′s Hospital, Henan Jiaozuo 454000, China
  • Received:2021-05-24 Revised:2021-09-08 Online:2021-10-28 Published:2021-10-28

摘要: 目的:分析左乙拉西坦联合舍曲林对癫痫伴抑郁患者的疗效、安全性及生活质量的影响。方法:选取本院2020年1月~2021年3月收治的癫痫伴抑郁患者114例,按数字抽签法将患者分为对照组和观察组,各57例。对照组患者给予左乙拉西坦治疗,观察组患者给予左乙拉西坦联合舍曲林治疗,均治疗6个月,比较两组患者治疗前后简易精神状态量表(MMSE)、汉密顿抑郁量表(HAMD)及癫痫患者生活质量量表-31(QOLIE-31)各项评分,观察治疗期间不良反应发生情况。结果:治疗前两组患者MMSE、HAMD评分比较差异均无统计学意义(P>0.05)。治疗后两组患者MMSE评分较治疗前均升高,观察组高于对照组(P<0.05);HAMD评分较治疗前均下降,观察组低于对照组(P<0.05)。治疗前两组患者QOLIE-31量表中认知领域、药物影响、社会功能、精力/疲劳、情绪、生活满意、癫痫发作担忧、总分评分比较差异均无统计学意义(P>0.05);治疗后两组患者QOLIE-31量表中认知领域、药物影响、社会功能、精力/疲劳、情绪、生活满意、癫痫发作担忧、总分评分较治疗前均升高,观察组均高于对照组(P<0.05)。两组患者不良反应总发生率比较差异无统计学意义(P>0.05)。结论:左乙拉西坦与舍曲林联合用药治疗癫痫伴抑郁患者,可有效减轻患者抑郁症状,改善患者认知功能,提高患者生活质量,安全性较好。
 

关键词: font-size:medium, ">癫痫;抑郁;左乙拉西坦;舍曲林;生活质量;安全性

Abstract: Objective: To analyze the effects of levetiracetam combined with sertraline on the efficacy, safety and quality of life in patients with epilepsy and depression. Methods: 114 patients with epilepsy and depression in our hospital from January 2020 to March 2021 were selected, which were divided into the control group and the observation group according to the digital lottery method, with 57 cases in each group. Patients in the control group were treated with levetiracetam, and patients in the observation group were treated with levetiracetam combined with sertraline for 6 months, the scores of Mini Mental State Scale (MMSE), Hamilton Depression Scale (HAMD) and epilepsy quality of life scale-31 (QOLIE-31) before and after treatment were compared between the two groups, observe the occurrence of adverse reactions during treatment. Results: Before treatment, there was no significant difference in MMSE and HAMD scores between the two groups of patients (P>0.05). After treatment, the MMSE scores of the two groups of patients were higher than those before treatment, and the observation group was higher than that of the control group (P<0.05). HAMD scores were lower than before treatment, and the observation group was lower than the control group (P<0.05). Before treatment, there were no significant differences between the two groups in QOLIE-31 cognitive domain, drug effect, social function, energy / fatigue, emotion, life satisfaction, epilepsy anxiety and total score (P>0.05). After treatment, the scores of cognitive domain, drug effect, social function, energy/fatigue, emotion, life satisfaction, epilepsy anxiety and total score of QOLIE-31 in the two groups were higher than those before treatment, and those in the observation group were higher than those in the reference group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion: The combination of levetiracetam and sertraline in the treatment of patients with epilepsy and depression can effectively reduce the symptoms of depression, improve the cognitive function of the patients, and improve the quality of life of the patients, with good safety.
   

Key words: font-size:medium, ">Epilepsy; Depression; Levetiracetam; Sertraline; Quality of life; Security

中图分类号: